Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Pharma News | BioPharma Dive
WEB3 days ago · The latest pharma news for biotech and biopharmaceutical professionals
Halozyme, doubling down on a licensing strategy, buys a drug …
WEBApr 13, 2022 · Dive Brief: Halozyme Therapeutics, a San Diego-based company whose business revolves around a type of drug delivery technology, announced Wednesday plans to expand its offerings through a nearly $1 billion acquisition of Antares Pharma.
Amgen completes $28B Horizon buyout that was challenged by FTC
WEBOct 6, 2023 · Amgen on Friday closed its $27.8 billion acquisition of Horizon Therapeutics, about one month after securing clearance from U.S. antitrust regulators who had challenged the deal.. With the acquisition’s completion, Amgen gains access to 12 drugs that had combined sales of $1.8 billion over the first six months of 2023. The company said it will update its sales guidance for the rest of the ...
CVS launches new venture in biosimilar drug experiment
WEBAug 24, 2023 · Dive Brief: Insurer CVS Health is getting into the market for lookalike biologic drugs, announcing Thursday the founding of a subsidiary called Cordavis to work directly with manufacturers of biosimilars in the U.S.; Alongside the announcement, CVS said it’s contracting with Novartis’ Sandoz division to sell under a private label its biosimilar to AbbVie’s Humira, called Hyrimoz, at an ...
J&J's new cancer drug leads a growing pipeline of dual-targeting ...
WEBMay 24, 2021 · The Food and Drug Administration's approval of Johnson & Johnson's Rybrevant on Friday marked only the third time a drug of its type has won regulatory clearance in the U.S., and just the second time to treat cancer.. Behind Rybrevant, though, is a growing pipeline of so-called bispecific antibodies, offering hope that physicians may be better able to treat difficult conditions like lymphoma ...
Akero shares soar as NASH drug succeeds in mid-stage trial
WEBSep 13, 2022 · Akero Therapeutics’ shares more than doubled in early trading on Tuesday after the company said an experimental medicine reduced the internal scarring of patients with the fatty liver disease nonalcoholic steatohepatitis in a mid-stage clinical trial.. Both tested doses of Akero’s drug, known as efruxifermin, met the study’s main goal, producing a statistically significant improvement in ...
Two decades and $200 billion: AbbVie’s Humira monopoly nears …
WEBMar 17, 2022 · All told, AbbVie filed about 250 patent applications for Humira in the U.S., 90% of them following the drug's 2002 approval, according to the advocacy group Initiative for Medicines, Access & Knowledge. One hundred and thirty have been granted. The strengthened patent shield has stretched AbbVie's legal monopoly in the U.S. for six years beyond the expiration of Humira's main patent in 2016.
Bristol Myers, Pfizer fend off a key challenge to their top-selling ...
WEBAug 6, 2020 · Dive Brief: A Delaware district court judge has upheld two key patents covering Bristol Myers Squibb and Pfizer's blockbuster blood-thinning drug Eliquis.; The judge ruled that generic versions of Eliquis from Sigmapharm, Sunshine Lake and Unichem infringe on composition of matter and formulation patents.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...